Medrx Co

Medrx Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medrx Co (4586.T) as of Nov 19, 2026 is -942.00 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -799.28 M JPY — a change of 17.86% (lower).

EBITDA

-942.00 MJPY

YoY

17.86%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medrx Co is 2025 -942.00 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medrx Co was 2024 -799.28 M JPY. It decreases by 17.86% lower compared to the previous year.

The Medrx Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.27 B JPY
Jan 1, 2019
-1.63 B JPY
Jan 1, 2020
-1.13 B JPY
Jan 1, 2021
-1.06 B JPY
Jan 1, 2022
-1.11 B JPY
Jan 1, 2023
-931.23 M JPY
Jan 1, 2024
-799.28 M JPY
Jan 1, 2025
-942.00 M JPY
The Medrx Co EBITDA history
YEAREBITDAYoY
-942.00 MJPY+17.86%
-799.28 MJPY-14.17%
-931.23 MJPY-15.73%
-1.11 BJPY+4.47%
-1.06 BJPY-6.13%
-1.13 BJPY-30.65%
-1.63 BJPY+27.92%
-1.27 BJPY+25.20%
-1.01 BJPY-24.24%
-1.34 BJPY+34.43%
-996.34 MJPY-0.30%
-999.30 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medrx Co is -942.00 M JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medrx Co changed from -799.28 M JPY to -942.00 M JPY, representing a 17.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medrx Co

All Key Metrics — Medrx Co